F. Fostira

发表

Large-scale genotyping identifies 41 new loci associated with breast cancer risk

Jaana M. Hartikainen, A. Hofman, A. Uitterlinden, 2013, Nature Genetics.

Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent

A. Whittemore, S. Cross, M. Beckmann, 2016, PLoS medicine.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, A. Whittemore, 2015, Nature Genetics.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Lara E. Sucheston-Campbell, 2017, Nature Genetics.

Leiden open variation database of the MUTYH gene

Peter Devilee, Florentia Fostira, Riccardo Fodde, 2010, Human mutation.

A distinct mutation on the alternative splice site of APC exon 9 results in attenuated familial adenomatous polyposis phenotype

F. Fostira, D. Yannoukakos, 2010, Familial Cancer.

Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes

William J. Astle, Dorothy A. Thompson, Sri V. V. Deevi, 2018, American journal of human genetics.

Candida albicans HWP1 gene expression and host antibody responses in colonization and disease.

F. Fostira, S. Challacombe, J. Staab, 2006, Journal of medical microbiology.

Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.

Wei Lu, Nina Ditsch, Julian Peto, 2013, American journal of human genetics.

Genetic evaluation based on family history and Her2 status correctly identifies TP53 mutations in very early onset breast cancer cases

D. Mavroudis, F. Fostira, D. Yannoukakos, 2015, Clinical genetics.

Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers

A. Whittemore, M. Beckmann, P. Fasching, 2020, Cancer Epidemiology, Biomarkers & Prevention.

Pitfalls in variant annotation for hereditary cancer diagnostics: The example of Illumina® VariantStudio®.

F. Fostira, D. Yannoukakos, I. Konstantopoulou, 2020, Genomics.

The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries

K. Kyriacou, B. Bonanni, O. Olopade, 2019, Human mutation.

Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study

F. Fostira, D. Yannoukakos, H. Gogas, 2012, Breast Cancer Research and Treatment.

Cancer gene‐panel testing identifies two loss‐of‐function alleles in PALB2 and PTEN

F. Fostira, P. Economopoulou, C. Avgerinou, 2018, Clinical genetics.

Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women.

F. Fostira, I. Konstantopoulou, Despoina Kalfakakou, 2020, JAMA.

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

F. Fostira, A. Antonacopoulou, H. Kalofonos, 2011, The Pharmacogenomics Journal.

Germline MBD4 deficiency causes a multi-tumor predisposition syndrome

M. Christie, D. Wedge, N. López-Bigas, 2022, American journal of human genetics.

Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2017, Clinical Genetics.

Epidemiological and clinicopathological characteristics of BRCA-positive and BRCA-negative breast cancer patients in Greece.

F. Fostira, D. Yannoukakos, C. Loghis, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Management and Long-Term Follow-Up of Hyperparathyroidism in Multiple Endocrine Neoplasia Type 1: Single Center Experience

F. Fostira, M. Yavropoulou, M. Tsoli, 2022, Journal of clinical medicine.

Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification.

F. Fostira, D. Yannoukakos, D. Loutradis, 2019, Cancer genetics.

Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3

W. Chung, R. Nussbaum, F. Couch, 2016, Breast Cancer Research and Treatment.

Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

W. Chung, F. Couch, B. Bonanni, 2020, JAMA oncology.

Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections.

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Clinical breast cancer.

Neoadjuvant treatment in ovarian cancer: New perspectives, new challenges

F. Fostira, H. Gogas, A. Psyrri, 2022, Frontiers in Oncology.

A Paternally Inherited BRCA1 Mutation Associated with an Unusual Aggressive Clinical Phenotype

F. Fostira, D. Yannoukakos, V. Georgoulias, 2014, Case reports in genetics.

Identiﬁcation of four novel susceptibility loci for oestrogen receptor negative breast cancer

Nussbaum, S. Cross, P. Fasching, 2016 .

Investigation of prognostic biomarkers in patients with urothelial carcinoma treated with platinum-based regimens.

F. Fostira, A. Charchanti, A. Psyrri, 2022, Urologic oncology.

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

Brigitte Rack, Seth Slettedahl, Heli Nevanlinna, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genetic Testing and Clinical Management Practices for Variants inNon-BRCA1/2 Breast (and Breast/Ovarian)Cancer Susceptibility Genes: An International Survey by the Evidence-BasedNetwork for the Interpretation of Germline Mutant Alleles (ENIGMA) ClinicalWorking Group

O. Olopade, C. Lázaro, S. Manoukian, 2019 .

Male breast cancer in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, F. Couch, 2018 .

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

W. Chung, D. Steinemann, F. Couch, 2022, Communications Biology.

Genetic analysis and clinical description of Greek patients with Peutz-Jeghers syndrome: Creation of a National Registry.

F. Fostira, D. Yannoukakos, G. Alexandrakis, 2018, Cancer genetics.

Crizotinib Failure in a TPM4-ALK-Rearranged Inflammatory Myofibroblastic Tumor With an Emerging ALK Kinase Domain Mutation.

F. Fostira, G. Fountzilas, P. Hytiroglou, 2017, JCO precision oncology.

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab in the first-line setting.

F. Fostira, A. Antonacopoulou, H. Kalofonos, 2010 .

MARGINAL: An Automatic Classification of Variants in BRCA1 and BRCA2 Genes Using a Machine Learning Model

G. Matsopoulos, F. Fostira, Despoina Kalfakakou, 2022, Biomolecules.

Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel.

F. Fostira, K. Papadopoulou, G. Fountzilas, 2022, Oncology letters.

Serum Concentration of Selected Angiogenesis-Related Molecules Differs among Molecular Subtypes, Body Mass Index and Menopausal Status in Breast Cancer Patients

F. Fostira, D. Manatakis, N. Vassos, 2022, Journal of clinical medicine.

Shared heritability and functional enrichment across six solid cancers

K. D. Sørensen, Stephanie A. Bien, Ali Amin Al Olama, 2018, bioRxiv.

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Jane E. Carpenter, S. Cross, M. Beckmann, 2011, Cancer research.

Breast-cancer risk in families with mutations in PALB2.

Nazneen Rahman, Katri Pylkäs, Arto Mannermaa, 2014, The New England journal of medicine.

Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness.

Stefania Tommasi, Laura Cortesi, Mads Thomassen, 2019, Cancer research.

Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries

F. Fostira, K. Papadopoulou, G. Fountzilas, 2021, Breast Cancer.

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants

D. Steinemann, F. Couch, B. Bonanni, 2020, Genetics in Medicine.

Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses

Jack A. Taylor, W. Chung, S. Cross, 2019, bioRxiv.

Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, F. Couch, 2017, Journal of the National Cancer Institute.

Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus

A. Whittemore, L. Kiemeney, S. Cross, 2016, Nature Communications.

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

D. Steinemann, F. Couch, B. Bonanni, 2016, PloS one.

Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2

R. Nussbaum, D. Steinemann, F. Couch, 2016, Breast Cancer Research.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2014, Breast Cancer Research.

Variant Interpretation in Patients With Metastatic Breast Cancer.

F. Fostira, I. Konstantopoulou, 2020, JAMA oncology.

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing

Raymond M. Moore, P. Fasching, F. Couch, 2018, Journal of the National Cancer Institute.

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

S. Cross, P. Fasching, C. Vachon, 2016, Journal of Medical Genetics.

A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor–negative breast cancer

Jane E. Carpenter, Peter Kraft, Gary K. Chen, 2011, Nature Genetics.

Transcriptome ‐ wide association study of breast cancer risk by estrogen ‐ receptor status

Jack A. Taylor, W. Chung, S. Cross, 2020 .

BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer.

S. Cross, M. Beckmann, A. Børresen-Dale, 2017, Cancer research.

Breast Cancer Susceptibility Genes

F. Fostira, A. Vratimos, P. Apostolou, 2015 .

Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.

F. Fostira, E. Giannoulatou, G. Lazaridis, 2019, Gynecologic oncology.

Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants

W. Chung, T. Fehm, T. Rebbeck, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hereditary Breast Cancer: The Era of New Susceptibility Genes

Florentia Fostira, F. Fostira, Paraskevi Apostolou, 2013, BioMed research international.

BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers.

Dong Liang, Patrick Neven, Harvey Risch, 2016, Journal of the National Cancer Institute.

Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2018, Journal of Human Genetics.

Extending the clinical phenotype associated with biallelic NTHL1 germline mutations

F. Fostira, D. Yannoukakos, E. Saloustros, 2018, Clinical genetics.

Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system

A. Papavassiliou, F. Fostira, D. Yannoukakos, 2019, Human mutation.

The fate of BRCA1-related germline mutations in triple-negative breast tumors.

F. Fostira, D. Yannoukakos, H. Gogas, 2017, American journal of cancer research.

Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade.

Jane E. Carpenter, Kyriaki Michailidou, France Labrèche, 2014, Human molecular genetics.

Tumor Genotyping and Homologous Recombination Repair Gene Variants in Patients With Epithelial Ovarian Cancer: Is Pathogenic Enough?

F. Fostira, E. Giannoulatou, G. Aravantinos, 2021, Frontiers in Oncology.

Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

Mads Thomassen, Nina Ditsch, Muhammad Usman Rashid, 2015, JAMA.

Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients

F. Fostira, D. Yannoukakos, G. Fountzilas, 2018, Journal of Human Genetics.

Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer

Jane E. Carpenter, A. Whittemore, W. Chung, 2016, Nature Communications.

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families.

Julie O. Culver, F. Couch, E. Goode, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores

F. Couch, O. Olopade, J. Benítez, 2021, Journal of the National Cancer Institute.

Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

D. Steinemann, F. Couch, O. Olopade, 2017, Journal of Clinical Oncology.

Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases

M. Dimopoulos, F. Fostira, D. Yannoukakos, 2013, PloS one.

A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

Jane E. Carpenter, Jack A. Taylor, W. Chung, 2021, Nature Communications.

Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.

Jane E. Carpenter, Kristen S Purrington, Victoria L. Cafourek, 2014, Carcinogenesis.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer

Lara E Sucheston-Campbell, Simon G. Coetzee, Dennis J. Hazelett, 2017, Nature Genetics.

Lung cancer as a predominant feature in a patient with Peutz–Jeghers syndrome: Case report

F. Fostira, K. Papadopoulou, G. Fountzilas, 2022, Thoracic cancer.

Physicians’ experience, practice and education, on genetic testing and genetic counseling: a nationwide survey study in Greece

F. Fostira, E. Fountzilas, E. Saloustros, 2022, Familial Cancer.

Screening of the DNA mismatch repair genes MLH1, MSH2 and MSH6 in a Greek cohort of Lynch syndrome suspected families

F. Fostira, D. Yannoukakos, I. Boukovinas, 2010, BMC Cancer.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

Christiana Kartsonaki, Mads Thomassen, Etienne Rouleau, 2011, Human molecular genetics.

Fine‐scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer

S. Cross, M. Beckmann, P. Fasching, 2016, International journal of cancer.

Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer

F. Fostira, D. Yannoukakos, D. Mauri, 2018, Breast Cancer Research and Treatment.

CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases.

F. Fostira, D. Yannoukakos, G. Voutsinas, 2015, Cancer genetics.

One in three highly selected Greek patients with breast cancer carries a loss-of-function variant in a cancer susceptibility gene

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Journal of Medical Genetics.

Genetic Testing and Clinical Management Practices for Variants in Non-BRCA1/2 Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group.

F. Couch, O. Olopade, R. Eeles, 2018, JCO precision oncology.

BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects

D. Mavroudis, V. Georgoulias, F. Fostira, 2020, International journal of cancer.

Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2015, PloS one.

Title Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA 1 and BRCA 2 mutation carriers

R. Nussbaum, D. Steinemann, V. Pankratz, 2015 .

Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk

S. Cross, M. Beckmann, P. Fasching, 2015, Cancer Epidemiology, Biomarkers & Prevention.

CanVaS: Documenting the genetic variation spectrum of Greek cancer patients

F. Fostira, D. Yannoukakos, I. Vlachos, 2021, Human mutation.

The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases

B. Bonanni, M. Urioste, J. Benítez, 2020, Cancers.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

W. Chung, M. Beckmann, P. Fasching, 2019, npj Breast Cancer.

A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation

F. Fostira, D. Yannoukakos, I. Konstantopoulou, 2019, Case reports in oncological medicine.

The Role of Phosphoinositide 3-Kinase C2α in Insulin Signaling*

D. James, F. Fostira, W. E. Hughes, 2007, Journal of Biological Chemistry.

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

F. Fostira, D. Yannoukakos, H. Gogas, 2009, British Journal of Cancer.

Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers

W. Chung, R. Nussbaum, D. Steinemann, 2014, Cancer Epidemiology, Biomarkers & Prevention.

CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects

F. Fostira, C. Papadimitriou, E. Fountzilas, 2021, Cancers.

Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry

A. Whittemore, S. Cross, M. Beckmann, 2016, Cancer Causes & Control.

Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma

F. Fostira, C. Papadimitriou, G. Aravantinos, 2021, Cancers.

Current practices on genetic testing in ovarian cancer

F. Fostira, C. Papadimitriou, Marios Papadimitriou, 2020, Annals of translational medicine.

Hereditary cancer syndromes.

F. Fostira, D. Yannoukakos, R. Sandaltzopoulos, 2007, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

The role of phosphoinositide 3-kinase C2alpha in insulin signaling.

D. James, F. Fostira, W. E. Hughes, 2007, The Journal of biological chemistry.

Asymptomatic Gastric Giant Polyp in a Boy with Peutz-Jeghers Syndrome Presented with Multiple Café Au Lait Traits

F. Fostira, M. Chorti, E. Christianakis, 2018, Case Reports in Surgery.

Turner's syndrome, autoimmune thyroiditis, and Crohn's disease in the same patient: a combination emphasizing the role of X-chromosome in inflammatory bowel disease patients.

F. Fostira, G. Terzoudi, J. Triantafillidis, 2010, Inflammatory bowel diseases.

Mutational spectrum of APC and genotype-phenotype correlations in Greek FAP patients

F. Fostira, D. Yannoukakos, R. Sandaltzopoulos, 2010, BMC Cancer.

Disease evolution and heterogeneity in bilateral breast cancer.

F. Fostira, E. Giannoulatou, K. Papadopoulou, 2016, American journal of cancer research.

High prevalence of BRCA1 founder mutations in Greek breast/ovarian families

F. Fostira, D. Yannoukakos, G. Fountzilas, 2014, Clinical genetics.

PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2019, Journal of Human Genetics.

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer-Beyond the Misdiagnosis.

F. Fostira, E. Fountzilas, V. Kotoula, 2019, JAMA Oncology.

Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece

F. Fostira, D. Yannoukakos, G. Voutsinas, 2017, Scientific Reports.

Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients

F. Fostira, D. Yannoukakos, G. Fountzilas, 2018, Journal of Human Genetics.

Germline loss-of-function variants in the base-excision repair gene MBD4 cause a Mendelian recessive syndrome of adenomatous colorectal polyposis and acute myeloid leukaemia

M. Christie, D. Wedge, N. López-Bigas, 2021, bioRxiv.

Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2

A. Whittemore, B. Karlan, E. John, 2023, British Journal of Cancer.

An In-Frame Exon-Skipping MUTYH Mutation Is Associated With Early-Onset Colorectal Cancer

F. Fostira, D. Yannoukakos, A. Efremidis, 2010, Diseases of the colon and rectum.

Î Rare Solitary Spinal Cord Metastasis after Epithelial Ovarian Cancer Diagnosis

F. Fostira, K. Papadopoulou, G. Fountzilas, 2020 .

Pathology of BRCA1- and BRCA2-associated breast cancers: known and less known connections

F. Fostira, D. Yannoukakos, C. Papadimitriou, 2016 .

Predisposing Germline Mutations in Young Patients With Squamous Cell Cancer of the Oral Cavity.

F. Fostira, G. Koutsodontis, A. Psyrri, 2018, JCO Precision Oncology.

ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

James M. Hodge, E. Burnside, Y. Kamatani, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer

Jane E. Carpenter, W. Chung, M. Beckmann, 2019, npj Breast Cancer.

Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing

P. Fasching, F. Couch, A. Cox, 2018 .

Hereditary Breast Cancer: The Era of New Susceptibility Genes

F. Fostira, Paraskevi Apostolou, 2013, BioMed research international.

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Sandra L. Halverson, A. Whittemore, L. Kiemeney, 2016, Gynecologic oncology.

Identification of six new susceptibility loci for invasive epithelial ovarian cancer

Yurii B. Shvetsov, Simon G. Coetzee, Dennis J. Hazelett, 2014, Nature Genetics.

Comprehensive Cancer-Predisposition Gene Testing in an Adult Multiple Primary Tumor Series Shows a Broad Range of Deleterious Variants and Atypical Tumor Phenotypes

K. Stirrups, C. Penkett, K. Megy, 2018, American journal of human genetics.

Leiden open variation database of the MUTYH gene

P. Devilee, F. Fostira, I. Fokkema, 2010, Human mutation.

Identification of a Novel IQCE Large Deletion through Copy Number Variant Analysis from Whole-Exome Sequencing Data of a Patient with Postaxial Polydactyly Type A7

F. Fostira, J. Traeger-Synodinos, K. Kosma, 2023, Molecular Syndromology.

Common breast cancer susceptibility loci are associated with triple-negative breast cancer.

Jane E. Carpenter, S. Cross, M. Beckmann, 2011, Cancer research.

Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.

V. Pankratz, F. Couch, T. Rebbeck, 2011, Human molecular genetics.

Culture of primary epithelial adenoma cells from familial adenomatous polyposis patients.

F. Fostira, D. Yannoukakos, A. Pintzas, 2008, Anticancer research.